Shares in Abbott Laboratories ($ABT) were down 4% in pre-market trading today as it announced that it planned to separate its global Nutrition business into an ...

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q3 2026, with sales up 14.5% year on year to $13.01 ...

Abbott (NYSE:ABT) reported third-quarter results that met earnings expectations and slightly exceeded revenue estimates, though shares are down around 1.4% premarket on Wednesday after the company ...

Abbott Laboratories (NYSE:ABT) has announced plans to spin off its Nutrition division into a separate publicly traded company ...

Shares of Abbott Laboratories ABT rallied 1.99% to $102.51 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising ...

A retrospective three-center study of 156 patients shows that a new ABT score, built from the alkaline phosphatase to ...

In the 1960s, the United States government wanted to find the best way to teach kids who were behind. A federal study called ...

For many people with cancer, completing treatment can bring a new uncertainty: Is my cancer really gone? Even after treatment, small amounts of cancer may remain in the body at levels that can be ...

XREAL One Pro+ vs One Pro: 1,200 nits vs 700, 60 fps 3D, same $599 price. See what changed, which size to buy, who should ...

Abbott (NYSE: ABT), the global healthcare leader, today announced its intention to separate its Nutrition business into an independent, publicly traded company that will be a global leader in the ...

Lutikizumab (ABT-981) met its primary end point and all 8 ranked secondary end points in the phase 3 INTREPID trial ...